Evotec SE（EVO）資訊與事件EVOEvotec SE

Evotec Appoints Joanna Holbrook as Chief Scientific Officer

Evotec (EVO) announced the appointment of Joanna Holbrook as chief scientific officer and member of the management board, effective November 1. Holbrook brings to Evotec more than 25 years of experience as both a scientist and R&D leader, applying novel technologies and data approaches to the challenges of drug discovery and advancing programs toward the clinic. Holbrook most recently served as Therapy Area Head, Cardiovascular, Renal and Hepatic Disease and Head of in vitro Discovery Platforms at Novo Nordisk (NVO).

Evotec Initiates Phase 1 Clinical Trial for JST-018

Evotec announced the initiation of a Phase 1 clinical trial evaluating JST-018, a cocktail of investigational monoclonal antibodies targeting orthopoxviruses, developed by its biologics CDMO subsidiary Just - Evotec Biologics under the U.S. Department of War's Accelerated Antibodies Program. Under the Accelerated Antibodies Program, Just - Evotec Biologics advanced the orthopoxvirus program from antibody sequence selection through preclinical development, process development, regulatory submission and cGMP manufacture of clinical trial materials. Manufacturing was completed at the company's J.POD facility in Redmond, Washington, utilizing its continuous bioprocessing platform.

Evotec and Plectonic Biotech Collaborate on Immunotherapy Research

Evotec and Plectonic Biotech announced a research collaboration to explore an immunotherapy approach for solid tumors. The collaboration addresses key challenges that have so far limited the successful application of traditional T cell engager therapies in solid tumors by combining Plectonic's programmable Logibody technology with Evotec's proprietary BiTco platform. By combining highly selective tumor recognition and enhanced T-cell activation, the companies will explore whether their integrated technologies can improve both the precision and potency of T-cell-engaging approaches in solid tumors. Under the terms of the agreement, the collaboration will generate preclinical proof-of-concept data to evaluate the potential of this new generation of T-cell-engaging approaches.